{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:39Z","timestamp":1788887079876,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10147-015-0834-3","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T13:41:16Z","timestamp":1431438076000},"page":"1063-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study"],"prefix":"10.1007","volume":"20","author":[{"given":"Masahiro","family":"Osawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikazu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyo","family":"Yoneoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"834_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","volume":"38","author":"XD Yang","year":"2001","unstructured":"Yang XD, Jia XC, Corvalan JR et al (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17\u201323","journal-title":"Crit Rev Oncol Hematol"},{"key":"834_CR2","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"834_CR3","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","volume":"110","author":"JR Hecht","year":"2007","unstructured":"Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980\u2013988","journal-title":"Cancer"},{"key":"834_CR4","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"834_CR5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/1078-0432.CCR-07-1509","volume":"14","author":"LM Weiner","year":"2008","unstructured":"Weiner LM, Belldegrun AS, Crawford J et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502\u2013508","journal-title":"Clin Cancer Res"},{"key":"834_CR6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","volume":"97","author":"S Siena","year":"2007","unstructured":"Siena S, Peeters M, Van Cutsem E et al (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469\u20131474","journal-title":"Br J Cancer"},{"key":"834_CR7","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"key":"834_CR8","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"834_CR9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jjco\/hyp016","volume":"39","author":"K Muro","year":"2009","unstructured":"Muro K, Yoshino T, Doi T et al (2009) A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 39:321\u2013326","journal-title":"Jpn J Clin Oncol"},{"key":"834_CR10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jjco\/hyt196","volume":"44","author":"N Boku","year":"2014","unstructured":"Boku N, Sugihara K, Kitagawa Y et al (2014) Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol 44:214\u2013223","journal-title":"Jpn J Clin Oncol"},{"key":"834_CR11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10147-012-0438-0","volume":"18","author":"Y Horiuchi-Yamamoto","year":"2013","unstructured":"Horiuchi-Yamamoto Y, Gemma A, Taniguchi H et al (2013) Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol 18:743\u2013749","journal-title":"Int J Clin Oncol"},{"key":"834_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-011-0199-0","volume":"6","author":"NA Barber","year":"2011","unstructured":"Barber NA, Ganti AK (2011) Pulmonary toxicities from targeted therapies: a review. Target Oncol 6:235\u2013243","journal-title":"Target Oncol"},{"key":"834_CR13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348\u20131357","journal-title":"Am J Respir Crit Care Med"},{"key":"834_CR14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","volume":"7","author":"K Nakagawa","year":"2012","unstructured":"Nakagawa K, Kudoh S, Ohe Y et al (2012) Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7:1296\u20131303","journal-title":"J Thorac Oncol"},{"key":"834_CR15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pds.1071","volume":"14","author":"LC Koo","year":"2005","unstructured":"Koo LC, Clark JA, Quesenberry CP et al (2005) National differences in reporting pneumonia and pneumonia interstitial: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 14:775\u2013787","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"834_CR16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10147-012-0494-5","volume":"17","author":"Y Saito","year":"2012","unstructured":"Saito Y, Gemma A (2012) Current status of DILD in molecular targeted therapies. Int J Clin Oncol 17:534\u2013541","journal-title":"Int J Clin Oncol"},{"key":"834_CR17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jjco\/hys005","volume":"42","author":"M Ishiguro","year":"2012","unstructured":"Ishiguro M, Watanabe T, Yamaguchi K et al (2012) A Japanese post-marketing surveillance of cetuximab [Erbitux(R)] in patients with metastatic colorectal cancer. Jpn J Clin Oncol 42:287\u2013294","journal-title":"Jpn J Clin Oncol"},{"key":"834_CR18","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549\u20132556","journal-title":"J Clin Oncol"},{"key":"834_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1272\/jnms.76.4","volume":"76","author":"A Gemma","year":"2009","unstructured":"Gemma A (2009) Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch 76:4\u20138","journal-title":"J Nippon Med Sch"},{"key":"834_CR20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/jjco\/hyu128","volume":"44","author":"T Sato","year":"2014","unstructured":"Sato T, Gemma A, Kudoh S et al (2014) Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. Jpn J Clin Oncol 44:1032\u20131039","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 2","key":"834_CR21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","volume":"91","author":"G Raghu","year":"2004","unstructured":"Raghu G, Nyberg F, Morgan G (2004) The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91(Suppl 2):S3\u2013S10","journal-title":"Br J Cancer"},{"key":"834_CR22","first-page":"1859","volume":"52","author":"H Mukai","year":"2011","unstructured":"Mukai H, Ohyashiki K, Katoh T et al (2011) Lung injury associated with bortezomib therapy in Japan. Rinsho Ketsueki 52:1859\u20131869 (in Japanese)","journal-title":"Rinsho Ketsueki"},{"key":"834_CR23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12282-013-0444-8","volume":"21","author":"S Noguchi","year":"2014","unstructured":"Noguchi S, Masuda N, Iwata H et al (2014) Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 21:703\u2013714","journal-title":"Breast Cancer"},{"key":"834_CR24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemoto M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137\u2013139","journal-title":"Lancet"},{"key":"834_CR25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","volume":"7","author":"D Makris","year":"2007","unstructured":"Makris D, Scherpereel A, Copin MC et al (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7:150","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"834_CR26","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","volume":"91","author":"P Camus","year":"2004","unstructured":"Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91(Suppl 2):S18\u2013S23","journal-title":"Br J Cancer"},{"key":"834_CR27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold MA, Wise AL, Speer MC et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:1503\u20131512","journal-title":"N Engl J Med"},{"key":"834_CR28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1164\/rccm.200804-550OC","volume":"178","author":"JT Cronkhite","year":"2008","unstructured":"Cronkhite JT, Xing C, Raghu G et al (2008) Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 178:729\u2013737","journal-title":"Am J Respir Crit Care Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0834-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0834-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:52:25Z","timestamp":1553640745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0834-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0834-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}